New York-based mobile apps company Button has secured $30 million in Series C funding, according to company database Crunchbase, topping the city’s recent funding headlines. The cash infusion was announced June 24 and led by Icon Ventures.
According to its Crunchbase profile, "Through higher-converting technology, Button embeds commerce inside publisher apps, so that brands can grow their mobile business, publishers can increase their mobile revenue, and consumers have a better buying experience on mobile. Intent is changing."
The five-year-old company has raised four previous funding rounds, including a $20 million Series B round in 2017.
The round brings total funding raised by New York companies in software over the past month to $733 million. The local software industry has produced 538 funding rounds over the past year, yielding a total of $9.2 billion in venture funding.
In other local funding news, organic food and dietary supplements company The Nue Co. announced a $9 million Series A funding round on June 25, led by Waldencast.
According to Crunchbase, "The Nue Co. was born after a trip to Copenhagen inspired us to create a supplement brand founded on two Danish principles, simplicity and creativity. Their lab has over 20 years experience and is based in Cambridge, England. Rather than working with harsh, isolated vitamins, they choose to work with powerful organic foods high in specific vitamins or minerals."
The company also raised a $1.5 million seed round in 2017.
Meanwhile, therapeutics and fitness company Alma Health raised $8 million in Series A funding, announced on June 21. The round's investors were led by Tusk Ventures.
According to the company's Crunchbase profile, "Alma is pioneering a new practice model for therapists to elevate the therapy experience and simplify access to care. Alma builds copracticing communities powered by shared technology and services."
Alma Health last raised $4.5 million in seed funding in 2018.
This story was created automatically using local investment data, then reviewed by an editor. Click here for more about what we're doing. Got thoughts? Go here to share your feedback.